Pioneering study aims to demonstrate the robustness of personalized medication analysis and recommendations for polypharmacy patients generated by MDI Health’s novel Artificial Pharmacology Intelligence (API).

MDI Health, a leader in personalized medication management and polypharmacy optimization, today announced a research collaboration with Stanford Medicine’s Healthcare AI Applied Research Team (HEA₃RT), a cutting-edge team at Stanford advancing responsible, effective, and scalable AI solutions in primary and population health.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250904994058/en/

Study Details:

The two organizations will launch a study that will further evaluate MDI’s Artificial Pharmacology Intelligence system that has demonstrated over 93% accuracy compared to an expert panel in reviewing polypharmacy patients (patients taking multiple chronic drug treatments).

Polypharmacy is a growing global concern caused by the rise of multiple chronic conditions in the aging population. Polypharmacy increases the risk of drug-related complications, which are considered one of the leading causes of death in the US, costing $528 billion annually.

Dr. Janjri Desai, Pharm.D., MBA, DPLA, Executive Director of Pharmacy and HEA₃RT collaborator, stated: "Optimizing medications for complex patients is one of the most pressing challenges in healthcare... . In today’s increasingly resource-constrained healthcare environment, AI tools can be leveraged to improve pharmacist (and physician) efficiency, ultimately improving access to care… . I’m looking forward to this research collaboration as an important step toward ensuring responsible integration of these technologies in clinical practice."

The study is expected to be completed in 2026. MDI’s API and Stanford’s clinical pharmacists will review ~200 patients’ 10+ years of medical and insurance data to separately provide personalized clinical recommendations for each individual to mitigate their specific risks. Both sets of recommendations will be independently reviewed by a ground truth committee composed of three senior clinical pharmacists for accuracy.

“Our mission has always been to drive meaningful innovation that delivers measurable impact,” said Dr. Dorit Dil Nahlieli, Pharm.D, Co-founder, President & Chief Scientist at MDI Health. “By collaborating with Stanford Medicine’s Healthcare AI Applied Research Team, we’re deepening our commitment to evidence-based innovation and helping accelerate the use of AI to scale personalized medication treatment for polypharmacy patients.”

About MDI Health

MDI Health is an advanced AI-driven medication management solution provider. MDI Health’s Artificial Pharmacology Intelligence (API) system personalizes and automates complex medication reviews, empowering clinicians to manage treatment for polypharmacy patients at scale, improving health outcomes and reducing medical costs. Its ability to provide context-aware, evidence-based clinical insights and recommendations is favored by clinicians and supports safer, more informed clinical decision-making.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250904994058/en/